Article Information
- Received September 21, 2016
- Revision received January 31, 2017
- Accepted February 10, 2017
- Published online February 21, 2017.
Author Information
- Panos Zanos1,
- Mackenzie E. Nelson2,
- Jaclyn N. Highland1,6,
- Samuel R. Krimmel5,
- Polymnia Georgiou1,
- Todd D. Gould1,3,4,5,6,‡ and
- Scott M. Thompson1,2,5,‡
- 1Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201
- 2Department of Physiology, University of Maryland School of Medicine, Baltimore, MD 21201
- 3Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD 21201
- 4Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD 21201
- 5Program in Neuroscience, University of Maryland School of Medicine, Baltimore, MD 21201
- 6Program in Toxicology, University of Maryland School of Medicine, Baltimore, MD 21201
- Correspondence should be addressed to Scott M. Thompson, Department of Physiology, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, MD 21201, E-mail: sthompson{at}som.umaryland.edu.
Author contributions
Author contributions: P.Z., T.D.G., and S.M.T. designed research; P.Z., J.H., M.E.N., S.R.K., and P.G. performed research; P.Z., J.H., S.R.K. analyzed data; P.Z., P.G., T.D.G., and S.M.T. wrote the paper.
Disclosures
T.D.G. has received consulting fees from Sunovion Pharmaceuticals and Janssen Pharmaceuticals and research funding from Janssen Pharmaceuticals and Roche Pharmaceuticals during the preceding three years. T.D.G. and P.Z. are listed as coinventors on a patent application for the use of ketamine metabolites, (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine, in the treatment of depression, anxiety, anhedonia, suicidal ideation, and posttraumatic stress disorders. T.D.G. and P.Z. have assigned their patent rights to the University of Maryland Baltimore but will share a percentage of any royalties that may be received by the University of Maryland Baltimore. S.M.T. is listed as a coinventor on a patent application for the use of negative allosteric modulators of GABA-A receptors containing α5 subunits as fast-acting antidepressants. He has assigned his patent rights to the University of Maryland Baltimore but will share a percentage of any royalties that may be received by the University of Maryland Baltimore. M.E.N., J.N.H., S.R.K., and P.G. declare no competing financial interests.
This work was supported by National Institute of Health Grants NH086828 (to S.M.T.) and MH107615 (to T.D.G.) as well as by a gift from the Kahlert Foundation (S.M.T.).
↵‡ Gould and Thompson are co-senior authors.
Funding
HHS NIH National Institute of Mental Health
NIMH R01 086828HHS NIH National Institute of Mental Health
MH R01 107615Kahlert Foundation
Other Version
- You are viewing the most recent version of this article.
- previous version (February 21, 2017).
Online Impact